<table border="0" cellpadding="0" cellspacing="0" width="883.12" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 3 Includes clinically significant drug interactions with buprenorphine and naloxone sublingual tablets 
			</caption>
<colgroup>
<col width="22.7409638554217%"></col>
<col width="77.2590361445783%"></col>
</colgroup>
<tbody>
<tr stylecode="Botrule">
<td colspan="2" stylecode="Lrule Rrule" valign="middle">
<content stylecode="bold">Benzodiazepines</content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">There have been a number of reports regarding coma and death associated with the misuse and abuse of the combination of buprenorphine and benzodiazepines. In many, but not all of these cases, buprenorphine was misused by self-injection of crushed buprenorphine tablets. Preclinical studies have shown that the combination of benzodiazepines and buprenorphine altered the usual ceiling effect on buprenorphine-induced respiratory depression, making the respiratory effects of buprenorphine appear similar to those of full opioid agonists.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Intervention:</content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">Closely monitor patients with concurrent use of buprenorphine and naloxone sublingual tablets and benzodiazepines. Warn patients that it is extremely dangerous to self-administer benzodiazepines while taking buprenorphine and naloxone sublingual tablets, and warn patients to use benzodiazepines concurrently with buprenorphine and naloxone sublingual tablets only as directed by their healthcare provider.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td colspan="2" stylecode="Lrule Rrule" valign="top">
<content stylecode="bold">Non-Benzodiazepine Central Nervous System (CNS) Depressants</content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">Due to additive pharmacologic effects, the concomitant use of non-benzodiazepine CNS depressants, including alcohol, can increase the risk of hypotension, respiratory depression, profound sedation, coma, and death.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Intervention:</content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">Reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients closely for signs of respiratory depression and sedation <content stylecode="italics">[see Warnings and Precautions (<linkhtml href="#Section_5.2">5.2</linkhtml>, <linkhtml href="#Section_5.3">5.3</linkhtml>)].</content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Examples:</content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">Alcohol, non-benzodiazepine sedatives/hypnotics, anxiolytics, tranquilizers, muscle relaxants, general anesthetics, antipsychotics, and other opioids.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="justify" colspan="2" stylecode="Lrule Rrule" valign="top">
<content stylecode="bold">Inhibitors of CYP3A4</content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">The concomitant use of buprenorphine and CYP3A4 inhibitors can increase the plasma concentration of buprenorphine, resulting in increased or prolonged opioid effects, particularly when an inhibitor is added after a stable dose of buprenorphine and naloxone sublingual tablets is achieved.<br/> <br/>After stopping a CYP3A4 inhibitor, as the effects of the inhibitor decline, the buprenorphine plasma concentration will decrease <content stylecode="italics">[see Clinical Pharmacology (<linkhtml href="#Section_12.3">12.3</linkhtml>)],</content> potentially resulting in decreased opioid efficacy or a withdrawal syndrome in patients who had developed physical dependence to buprenorphine.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Intervention:</content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">If concomitant use is necessary, consider dosage reduction of buprenorphine and naloxone sublingual tablets until stable drug effects are achieved. Monitor patients for respiratory depression and sedation at frequent intervals.<br/> <br/>If a CYP3A4 inhibitor is discontinued, consider increasing the buprenorphine and naloxone sublingual tablets dosage until stable drug effects are achieved. Monitor for signs of opioid withdrawal.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Examples:</content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">Macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g. ketoconazole), protease inhibitors (e.g., ritonavir)<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="justify" colspan="2" stylecode="Lrule Rrule" valign="top">
<content stylecode="bold">CYP3A4 Inducers</content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">The concomitant use of buprenorphine and CYP3A4 inducers can decrease the plasma concentration of buprenorphine <content stylecode="italics">[see Clinical Pharmacology (<linkhtml href="#Section_12.3">12.3</linkhtml>)],</content> potentially resulting in decreased efficacy or onset of a withdrawal syndrome in patients who have developed physical dependence to buprenorphine.<br/> <br/>After stopping a CYP3A4 inducer, as the effects of the inducer decline, the buprenorphine plasma concentration will increase <content stylecode="italics">[see Clinical Pharmacology (<linkhtml href="#Section_12.3">12.3</linkhtml>)],</content> which could increase or prolong both therapeutic effects and adverse reactions and may cause serious respiratory depression.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Intervention:</content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">If concomitant use is necessary, consider increasing the buprenorphine and naloxone sublingual tablets dosage until stable drug effects are achieved. Monitor for signs of opioid withdrawal.<br/> <br/>If a CYP3A4 inducer is discontinued, consider buprenorphine and naloxone sublingual tablets dosage reduction and monitor for signs of respiratory depression.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Examples:</content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">Rifampin, carbamazepine, phenytoin<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="justify" colspan="2" stylecode="Lrule Rrule" valign="top">
<content stylecode="bold">Antiretrovirals: Non-nucleoside reverse transcriptase inhibitors (NNRTIs)</content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are metabolized principally by CYP3A4. Efavirenz, nevirapine, and etravirine are known CYP3A inducers, whereas delaviridine is a CYP3A inhibitor. Significant pharmacokinetic interactions between NNRTIs (e.g., efavirenz and delavirdine) and buprenorphine have been shown in clinical studies, but these pharmacokinetic interactions did not result in any significant pharmacodynamic effects.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Intervention:</content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">Patients who are on chronic buprenorphine and naloxone sublingual tablets treatment should have their dose monitored if NNRTIs are added to their treatment regimen.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Examples:</content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">efavirenz, nevirapine, etravirine, delavirdine<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="justify" colspan="2" stylecode="Lrule Rrule" valign="top">
<content stylecode="bold">Antiretrovirals: Protease inhibitors (PIs)</content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">Studies have shown some antiretroviral protease inhibitors (PIs) with CYP3A4 inhibitory activity (nelfinavir, lopinavir/ritonavir, ritonavir) have little effect on buprenorphine pharmacokinetic and no significant pharmacodynamic effects. Other PIs with CYP3A4 inhibitory activity (atazanavir and atazanavir/ritonavir) resulted in elevated levels of buprenorphine and norbuprenorphine, and patients in one study reported increased sedation. Symptoms of opioid excess have been found in postmarketing reports of patients receiving buprenorphine and atazanavir with and without ritonavir concomitantly.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Intervention:</content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">Monitor patients taking buprenorphine and naloxone sublingual tablets and atazanavir with and without ritonavir, and reduce dose of buprenorphine and naloxone sublingual tablets if warranted.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Examples:</content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">atazanavir, ritonavir<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="justify" colspan="2" stylecode="Lrule Rrule" valign="top">
<content stylecode="bold">Antiretrovirals: Nucleoside reverse transcriptase inhibitors (NRTIs)</content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">Nucleoside reverse transcriptase inhibitors (NRTIs) do not appear to induce or inhibit the P450 enzyme pathway, thus no interactions with buprenorphine are expected.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Intervention:</content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">None<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="justify" colspan="2" stylecode="Lrule Rrule" valign="top">
<content stylecode="bold">Serotonergic Drugs</content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system has resulted in serotonin syndrome.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Intervention:</content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation and dose adjustment. Discontinue buprenorphine and naloxone sublingual tablets if serotonin syndrome is suspected.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Examples:</content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="justify" colspan="2" stylecode="Lrule Rrule" valign="top">
<content stylecode="bold">Monoamine Oxidase Inhibitors (MAOIs)</content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">MAOI interactions with opioids may manifest as serotonin syndrome or opioid toxicity (e.g., respiratory depression, coma).<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Intervention:</content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">The use of buprenorphine and naloxone sublingual tablets is not recommended for patients taking MAOIs or within 14 days of stopping such treatment.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Examples:</content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">phenelzine, tranylcypromine, linezolid<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="justify" colspan="2" stylecode="Lrule Rrule" valign="top">
<content stylecode="bold">Muscle Relaxants</content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">Buprenorphine may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Intervention:</content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">Monitor patients receiving muscle relaxants and buprenorphine and naloxone sublingual tablets for signs of respiratory depression that may be greater than otherwise expected and decrease the dosage of buprenorphine and naloxone sublingual tablets and/or the muscle relaxant as necessary.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="justify" colspan="2" stylecode="Lrule Rrule" valign="top">
<content stylecode="bold">Diuretics</content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Intervention:</content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">Monitor patients for signs of diminished diuresis and/or effects on blood pressure and increase the dosage of the diuretic as needed.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="justify" colspan="2" stylecode="Lrule Rrule" valign="top">
<content stylecode="bold">Anticholinergic Drugs</content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">The concomitant use of anticholinergic drugs may increase the risk of urinary retention and/or severe constipation, which may lead to paralytic ileus.<br/>
</td>
</tr>
<tr>
<td stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Intervention:</content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">Monitor patients for signs of urinary retention or reduced gastric motility when buprenorphine and naloxone sublingual tablets are used concomitantly with anticholinergic drugs.<br/>
</td>
</tr>
</tbody>
</table>